Arrowhead Pharmaceuticals Inc

2 wrz 2026, 23:01 UTC

Arrowhead Pharmaceuticals Inc is trading lower in after-market hours, reflecting a notable decline since Wednesday's close amid broader market tensions and rising oil prices.

1 wrz 2026, 19:46 UTC

HC Wainwright reiterated its Buy rating on Arrowhead Pharmaceuticals, maintaining a $120 price target as shares advance during the session.

31 sie 2026, 20:01 UTC

Arrowhead Pharmaceuticals shares are lower despite promising Phase 3 results for plozasiran, which showed significant triglyceride reductions in patients.

28 sie 2026, 21:01 UTC

Arrowhead Pharmaceuticals Inc. shares are higher in after-market trading, continuing a modest rise since Friday's close, despite remaining below the 20-day moving average.

26 sie 2026, 19:56 UTC

Arrowhead Pharmaceuticals shares are lower today, trading within a narrow range without any specific news or developments identified.

25 sie 2026, 23:31 UTC

Arrowhead Pharmaceuticals shares moved higher in after-market trading, remaining near the upper end of their one-month range. No specific news was identified.

21 sie 2026, 19:46 UTC

Arrowhead Pharmaceuticals shares are lower as Director Michael Perry sold 11,600 shares, reducing his ownership. Rising Treasury yields may also affect sentiment in biotechnology.

20 sie 2026, 21:26 UTC

Arrowhead Pharmaceuticals Inc shares are lower during after-market hours. Broader market pressure from rising U.S. Treasury yields may be influencing sentiment.

19 sie 2026, 19:26 UTC

Arrowhead Pharmaceuticals shares are higher Wednesday, supported by gains in the biotech sector, as the stock remains above its 20-day moving average.

18 sie 2026, 23:01 UTC

Arrowhead Pharmaceuticals shares are lower in after-market hours, continuing a decline since Tuesday's close amid broader market concerns over rising U.S. Treasury yields.

14 sie 2026, 19:26 UTC

Arrowhead Pharmaceuticals Inc shares are higher during Friday's session, trading above their 20-day moving average and near the top of their one-month range.

13 sie 2026, 20:06 UTC

Arrowhead Pharmaceuticals Inc is declining today amid broader sector pressures, reflecting challenges in the biotech sector linked to the performance of LABU.

12 sie 2026, 21:01 UTC

Arrowhead Pharmaceuticals shares are higher in after-market hours, buoyed by positive market sentiment following comments on interest rates from Economic Advisor Phelan.

11 sie 2026, 19:36 UTC

Arrowhead Pharmaceuticals Inc is trading higher today, remaining above its 20-day moving average amid geopolitical tensions and anticipation of U.S. inflation reports.

6 sie 2026, 19:16 UTC

Arrowhead Pharmaceuticals Inc shares are lower during Thursday's session, despite earlier rebounding from a session high. No specific news was identified to explain the decline.

5 sie 2026, 21:36 UTC

Arrowhead Pharmaceuticals Inc is trading higher in after-market hours, reflecting strong performance and positioning above its 20-day moving average.

4 sie 2026, 23:02 UTC

Arrowhead Pharmaceuticals shares fell in after-market trading following a net loss of $194.280 million and an EPS of -$1.36 in its fiscal Q3 results.

3 sie 2026, 19:36 UTC

Arrowhead Pharmaceuticals Inc is trading higher in Monday's session. Broader market positivity follows President Trump's military announcement, impacting crude oil prices.

31 lip 2026, 19:16 UTC

Arrowhead Pharmaceuticals shares are lower, reflecting broader pressures in the biotechnology sector amid rising inflation concerns linked to increased crude oil prices.

30 lip 2026, 23:06 UTC

Arrowhead Pharmaceuticals Inc shares declined in after-market trading, with no specific news identified to explain the movement amid broader market volatility.

29 lip 2026, 20:09 UTC

RBC Capital raised Arrowhead Pharmaceuticals' price target to $100 from $87, contributing to positive sentiment and modest gains since Tuesday's close.

28 lip 2026, 23:31 UTC

Arrowhead Pharmaceuticals shares are lower in after-market trading, continuing a decline since Tuesday's close amid broader market weakness and significant declines in other indices.

27 lip 2026, 19:02 UTC

Arrowhead Pharmaceuticals completed enrollment in its Phase 3 YOSEMITE trial for zodasiran, with H.C. Wainwright and Morgan Stanley raising price targets to $115 and $120, respectively.

24 lip 2026, 19:12 UTC

Morgan Stanley raised its price target for Arrowhead Pharmaceuticals to $120, but shares are trading lower amid increased market volume during Friday's session.

23 lip 2026, 10:16 UTC

Arrowhead Pharmaceuticals shares rise in pre-market trading, building on Wednesday's gains after positive drug trial results and a price target increase to $115 from $90.

22 lip 2026, 22:06 UTC

Arrowhead Pharmaceuticals reported positive topline results from its Phase 3 SHASTA-3 and SHASTA-4 studies, boosting shares higher in after-market trading.

21 lip 2026, 20:12 UTC

Arrowhead Pharmaceuticals Inc. shares declined in after-market trading, remaining below the 20-day moving average and near the lower end of the one-month range.

20 lip 2026, 20:21 UTC

Arrowhead Pharmaceuticals Inc shares are lower in after-market hours, declining from a high to a low amid unusual trading activity and no specific news identified.